Fibroblast growth factor: A target for covid-19 infection
In the last few months, covid-19 has spread as a highly contagious pandemic. Currently no therapies have proven to be effective for the treatment of this severe illness that progresses with a strong inflammation in different organs and systems. Because fibroblast growth factor (FGF) is a potent inflammatory agent, we have tested, in one patient who didnt respond to the protocol therapy, the effect of FGF inhibition with an anti-inflammatory and antiviral compound with a large history of medical use which was reported as the most effective anti-FGF inhibitor: dobesilate. After five days of oral treatment, dobesilate resulted in amelioration of chest radiographies as well as in clinical improvement, opening a new possible therapeutic mean to be tested in patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
International Journal of Medical Reviews and Case Reports - 4(2020), 5, Seite 122-125 |
| Sprache: |
Englisch ; Portugiesisch |
|---|
| Beteiligte Personen: |
Pedro Cuevas [VerfasserIn] |
|---|
| Links: |
dx.doi.org [kostenfrei] |
|---|
| Themen: |
Covid-19 infection |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
DOAJ000641936 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ000641936 | ||
| 003 | DE-627 | ||
| 005 | 20230311012353.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2020 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)DOAJ000641936 | ||
| 035 | |a (DE-599)DOAJbe8cdb2fa82e4eb3bbe430b884f9a1a5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a por | ||
| 100 | 0 | |a Pedro Cuevas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fibroblast growth factor: A target for covid-19 infection |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a In the last few months, covid-19 has spread as a highly contagious pandemic. Currently no therapies have proven to be effective for the treatment of this severe illness that progresses with a strong inflammation in different organs and systems. Because fibroblast growth factor (FGF) is a potent inflammatory agent, we have tested, in one patient who didnt respond to the protocol therapy, the effect of FGF inhibition with an anti-inflammatory and antiviral compound with a large history of medical use which was reported as the most effective anti-FGF inhibitor: dobesilate. After five days of oral treatment, dobesilate resulted in amelioration of chest radiographies as well as in clinical improvement, opening a new possible therapeutic mean to be tested in patients. | ||
| 650 | 4 | |a covid-19 infection | |
| 650 | 4 | |a fibroblast growth factor | |
| 650 | 4 | |a dobesilate | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Antonio Manquillo |e verfasserin |4 aut | |
| 700 | 0 | |a Pedro Guillen |e verfasserin |4 aut | |
| 700 | 0 | |a Guillermo Giménez-Gallego |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International Journal of Medical Reviews and Case Reports |d International Sci Ink Press Ltd, 2018 |g 4(2020), 5, Seite 122-125 |w (DE-627)DOAJ000092606 |x 25349821 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2020 |g number:5 |g pages:122-125 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5455/IJMRCR.Fibroblast-growth-factor-COVID-19 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/be8cdb2fa82e4eb3bbe430b884f9a1a5 |z kostenfrei |
| 856 | 4 | 0 | |u https://mdpub.net/index.php?fulltxt=103656&fulltxtj=172&fulltxtp=172-1588335350.pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2534-9821 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2020 |e 5 |h 122-125 | ||